Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

steven boyd, biotech stock review

April 2019 Offering

On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors for the sale by us of an aggregate of 3,430,421 shares of our common stock at a purchase price of $1.545 per share. Concurrently with the sale of the shares, pursuant to the securities purchase agreements, we also sold to the investors unregistered warrants to purchase an aggregate of up to 3,430,421 shares of our common stock. The offering closed on April 3, 2019.

Our Executive Chairman, Leonard Mazur, purchased 1,165,048 shares of common stock and warrants to purchase up to 1,165,048 shares of our common stock for $1.8 million. Our director and Chief Executive Officer, Myron Holubiak, purchased 129,450 shares of common stock and warrants to purchase up to 129,450 shares of our common stock for $200,000. The purchases by Messrs. Mazur and Holubiak were on the same terms as were offered to the public.

September 2019 Offering

On September 25, 2019, Citius entered into an underwriting agreement with H.C. Wainwright & Co., LLC, relating to an underwritten at-the-market offering of (i) 6,760,615 units, with each unit being comprised of one share of the Company’s common stock, par value $0.001 per share, and one warrant to purchase one share and (ii) 1,060,615 pre-funded units, with each pre-funded unit being comprised of one pre-funded warrant to purchase one share and one warrant, which closed on September 27, 2019. The offering price was $0.8951 per unit and $0.895 per pre-funded unit.

Armistice Capital Master Fund, Ltd. (“Armistice”), our largest outside stockholder, purchased 3,910,615 shares of common stock, pre-funded warrants to purchase up to 1,060,615 shares of common stock, and warrants to purchase up to 3,910,615 shares of our common stock for $4,976,785. Our Executive Chairman, Leonard Mazur, purchased 2,234,700 shares of common stock and warrants to purchase up to 2,234,700 shares of our common stock for approximately $2.0 million. Our director and Chief Executive Officer, Myron Holubiak, purchased 558,597 shares of common stock and warrants to purchase up to 558,597 shares of our common stock for 500,000. The purchases by Armistice and Messrs. Mazur and Holubiak were on the same terms as were offered to the public.

Read Full Filing in NOTICE OF ANNUAL MEETING OF STOCKHOLDERS, To Be Held On February 10, 2020

Armistice Capital Website

News & Filings, Armistice